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Angiographic Findings in Patients With Refractory Unstable
Angina According to Troponin T Status
Christopher Heeschen, MD; Marcel J. van den Brand, MD; Christian W. Hamm, MD;
Maarten L. Simoons, MD; for the CAPTURE Investigators
Background—The CAPTURE (C7E3 fab AntiPlatelet Therapy in Unstable REfactory angina) trial enrolled patients with
refractory unstable angina and documented a therapeutic benefit for abciximab, a platelet glycoprotein IIb/IIIa receptor
antagonist, that was particularly evident in patients with elevated troponin T (TnT) levels. In the current study, we
related the angiographic data to the TnT status of the CAPTURE patients.
Methods and Results—In 853 patients, angiographic data at baseline and 18 to 24 hours after treatment were available and
assessed by an Angiographic Committee with respect to TIMI flow, lesion severity, and visibility of thrombus. TnT
levels .0.1 mg/L were found in 30.9% of the patients. Before randomization, thrombus was visible in 14.6% of
TnT-positive patients (TnT levels .0.1 mg/L) and 4.2% of TnT-negative patients (P50.004). Complex lesion
characteristics B21/C (72.0% versus 53.9%; P,0.001) and TIMI flow ,2 (15.6% versus 5.1%; P,0.001) were more
frequent in TnT-positive patients. Abciximab was effective with respect to reduction of visible thrombus, increase of
TIMI flow, and reduction of cardiac events in TnT-positive patients only. Multivariate analysis identified TnT status,
but not angiographic findings, as an independent predictor for both outcome and efficacy of treatment with abciximab.
Conclusions—Complex lesion characteristics and visible thrombus formation at baseline were significantly linked to TnT
elevation. However, TnT status was a more powerful predictor of increased cardiac risk and efficacy of treatment with
abciximab than either. Relative to the angiogram, TnT can thus be considered a more sensitive marker for the underlying
pathology, identifying patients with unstable angina who will particularly benefit from antiplatelet treatment.
(Circulation. 1999;104:1509-1514.)
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Unstable angina is a critical phase of coronary heartdisease that is defined mainly by clinical symptoms1; an
increased risk of myocardial infarction and death exists,
particularly 72 hours after the onset of symptoms.2–4
Postmortem studies in patients with unstable angina have iden-
tified erosion or rupture of the fibrous cap of the atherosclerotic
plaque as the initial event.5,6 Exposure of plaque contents, collagen,
and other components of the vascular wall lead to increased
vascular tone and platelet activation.7 Intracoronary thrombus for-
mation and systemic activation of coagulation have been demon-
strated in these patients with unstable angina pectoris.8,9
In about one-third of patients with unstable angina pectoris,
elevated troponin T (TnT) levels (.0.1 mg/L) can be ob-
served. This subgroup of patients has a particularly high risk
of death and acute myocardial infarction (AMI).3,4 Even when
enzyme activity of creatine kinase remains within the normal
range, TnT-positive patients have a 5- to 10-fold higher
incidence of cardiac events during 30-day follow-up.3,4,10–15
Currently, it is suggested that TnT elevation is related to the
focal cell necrosis caused by thrombotic embolization from
friable thrombus formation.5,8
The database of the CAPTURE study (C7E3 AntiPlatelet
Therapy in Unstable REfractory angina) provides a unique
opportunity to test this hypothesis because both angiographic
information and TnT status are available for the majority of
patients. The CAPTURE study was designed to assess out-
come in patients with refractory angina who received either
abciximab or placebo up to 24 hours before scheduled
percutaneous transluminal coronary angioplasty (PTCA). We
investigated the relationship between angiographic lesion
characteristics and TnT release. Additionally, we compared
the predictive value of TnT and angiographic findings regard-
ing both cardiac events and the salutary effects of abciximab.
Methods
Patients
In the CAPTURE trial, 1265 patients (61% were men; all were aged
61610 years) were prospectively enrolled between May 1993 and
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December 1995.2 All patients had chest pain at rest associated with
electrocardiographic changes, despite treatment with intravenous
heparin and glyceryl trinitrate for $2 hours. All patients underwent
coronary angiography before randomization, which indicated signif-
icant coronary artery disease with a culprit lesion suitable for
angioplasty. Coronary intervention was scheduled 1 day later, 18 to
24 hours after the start of study medication. The patients were
randomly assigned to receive abciximab or placebo, which was
started within 2 hours of allocation and continued until 1 hour after
completion of the procedure. For cardiac events (defined as death
and nonfatal myocardial infarction), 4 time horizons were considered
in this study:
● #36 hours before PTCA
● #72 hours after randomization
● 30-day follow-up
● 6-month follow-up
Myocardial infarction during the index hospital stay was defined by
a creatine kinase enzyme activity value .3 times the upper limit of
normal in at least 2 samples. Myocardial infarction after discharge
was defined as a creatine kinase enzyme activity value .2 times the
upper limit of normal.2
Coronary Angiogram
Initial coronary angiography was performed before randomization,
and angiography was repeated 18 to 24 hours after the start of
treatment (placebo or abciximab). All angiograms were assessed
centrally for TIMI flow and characteristics of the culprit lesion by the
Angiographic Committee at Cardialysis, Rotterdam, the Netherlands.
The lesions were classified according to the American Heart Asso-
ciation/American College of Cardiology grading system.
Additional data regarding collateral flow and visibility of throm-
bus formation were collected at the time of randomization and after
pretreatment but before intervention, respectively. Thrombus forma-
tion was strictly defined as either a filling defect or haziness without
calcification near the lesion visible on at least 2 orthogonal views or
as an embolus in the distal territory of the related artery. The
responsible operator at each center documented the necessity of stent
implantation and PTCA-related complications.2
Analytical Techniques
Serum samples were collected in 1088 patients at the time of
allocation and stored centrally at 280°C. All analyses in the samples
were performed at the research laboratory of the University of
Hamburg; analysts were blinded regarding patient history, angio-
graphic data, and allocated treatment. We used a 1-step enzyme
immunoassay with electrochemiluminescent technology and mag-
netic microparticles carrying second-generation monoclonal capture
antibodies (Elecsys 2010, Boehringer Mannheim). A diagnostic
threshold value of 0.1 mg/L was used to classify patients as
TnT-positive.16–18 The applied internal controls interassay precision
was 6.7% at 0.12 mg/L and 4.1% at 0.56 mg/L.
In addition, creatine kinase MB mass was measured in parallel on
the Elecsys 2010 system. The detection limit of this test was 0.15
mg/L, and a diagnostic threshold level of 5 mg/L was used. The
interassay coefficient of variation obtained was 8.4% at 8.2 mg/L and
7.2% at 14.7 mg/L, with internal controls.
Statistical Methods
Continuous variables are expressed as means6SD. Comparison be-
tween groups was performed with Mann-Whitney U tests (2-sided).
Comparisons of categorical variables were performed by Fisher’s exact
test. We set the level of statistical significance at P,0.05.
The treatment effect of abciximab in terms of odds ratios (OR),
including 95% confidence intervals (CI), was assessed by logistic
regression analysis for different subgroups of patients regarding
angiographic findings and TnT status. TnT status and angiographic
findings of the patients were encoded as dichotomous variables. All
variables documented to be associated with short- or long-term
cardiac risk were used for reverse stepwise logistic regression
analysis to identify variables of independent predictive value.19,20
Variables that were not significantly associated with adverse out-
come in this regression model (P,0.05) were dropped. All calcula-
tions were done with SPSS 8.0.1 (SPSS Inc) or StatXact-3 (Cytel
Software Corp) software.
Results
We obtained complete data, including angiograms at baseline
and before coronary intervention and TnT determination, from
90% of the 1265 patients randomized in the CAPTURE study
data. In this subset, 183 patients were excluded from the analysis
due to an AMI #14 days before enrollment because TnT levels
may remain elevated for up to 14 days after such an event. In
these patients, TnT elevation does not necessarily reflect acute
myocardial injury before enrollment. The baseline characteris-
tics of the remaining subset of the study population (n5853
patients) were not different than the total study population with
respect to age, sex, cardiovascular risk profile, and concomitant
treatment before and after randomization.
In the subset population, 5.4% of patients receiving abcix-
imab suffered from major cardiac events (death or nonfatal
AMI) during the 30-day follow-up period versus 9.4% of
placebo-treated patients (P50.008). This benefit of treatment
is comparable to the results achieved in the complete study
population (4.8% versus 9.0%, respectively; P50.003). This
absolute difference in event rates of 4.2% was largely
maintained during the 6-month follow-up, although it was no
longer statistically significant (12.3% versus 8.8%; P50.14).
Angiographic Findings and Treatment Efficacy
Lesion Characteristics
The baseline angiogram revealed no differences in lesion
characteristics and TIMI flow between the placebo and
abciximab groups. Lesion characteristics were predictive of
both adverse outcome and efficacy of treatment with abcix-
imab. At the 30-day follow-up, patients with type A or B1
lesions had an incidence of death or AMI of 3.5% when
allocated to abciximab and of 5.1% when given placebo
(P50.59). In contrast, for patients with more complex le-
sions, abciximab significantly reduced cardiac risk. For pa-
tients with type B21 lesions, event rates were 4.9% when
treated with abciximab versus 11.7% for placebo (P50.04),
and for patients with type B21 or C lesions, the rates were
5.6% and 12.4%, respectively (P50.05). Thus, patients in the
placebo group with more complex lesion characteristics
(types B2/C) were at highest cardiac risk for death and AMI
(OR, 2.5; 95% CI, 1.3 to 3.1; P50.03). This increased risk was
reduced in patients with less complex lesions who were treated
with abciximab (OR, 1.4; 95% CI, 0.7 to 1.9; P50.43).
TIMI Flow
TIMI flow did not increase significantly from baseline to the
pre-PTCA angiogram, independent of allocated treatment. In
69.8% of patients receiving placebo, TIMI 3 flow was
documented at baseline, and incidence was unchanged before
coronary intervention (69.6%; P51.00). For patients allo-
cated to abciximab, TIMI 3 flow was observed in 68.5% of
patients at baseline versus 72.4% before angioplasty
(P50.35). In patients with TIMI 0 and 1 flow, improvement
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of vessel patency just missed statistical significance (P50.08)
for treatment with abciximab.
Thrombus
Visible thrombus was documented in 7.4% of initial angio-
grams. No difference was observed regarding mean duration
of the preceding heparin therapy between patients with and
without a visible thrombus (12.4 versus 11.9 hours; P50.61).
During the 18 to 24 hours of treatment before scheduled
angioplasty, thrombus resolved in 26.5% of patients treated
with placebo and 49.5% of patients treated with abciximab
(P50.02). Regardless of study group, no patient under
treatment with aspirin and intravenous heparin developed
new thrombus formations.
TnT Subgroup Analysis
A TnT concentration .0.1 mg/L at baseline (TnT-positive)
was documented in 30.9% of the patients with refractory
unstable angina. The baseline characteristics of the 264
patients above (positive) and the 589 patients below (nega-
tive) the threshold level of 0.1 mg/L are shown in Table 1; no
significant differences existed between the subgroups.
Lesion Characteristics
Patients with elevated TnT levels had more complex lesion
characteristics in baseline coronary angiograms. In 72.0% of
patients with a TnT concentration .0.1 mg/L, type B21 or C
lesions were documented (Figure 1). In contrast, only 28.0%
of the patients with TnT values .0.10 mg/L had type A or B1
lesions compared with 46% of patients with TnT concentra-
tions #0.1 mg/L (P,0.001).
TIMI Flow
TIMI flow at baseline was normal in 59.4% of the TnT-
positive patients and 74.5% of the TnT-negative patients
TABLE 1. Baseline Characteristics According to TnT Status
TnT-Positive TnT-Negative
Abciximab Placebo Abciximab Placebo
n 131 132 295 294
Male sex 75.7% 66.9% 70.1% 73.6%
Age, y 62.4610.6 62.7610.5 60.169.3 60.9 610.2
History of
Angina .4 wk 41.9% 39.6% 53.9% 64.5%
Infarction 14–30 d 2.9% 2.2% 4.2% 3.2%
Infarction .30 d 19.1% 15.8% 20.5% 22.8%
PTCA 11.8% 8.6% 15.9% 18.6%
CABG 1.5% 3.6% 1.3% 3.3%
Risk factors
Diabetes 13.2% 11.5% 13.3% 9.4%
Hypertension 35.3% 35.9% 37.3% 37.1%
Current smokers 41.2% 41.0% 39.6% 41.7%
Medication before enrollment
Aspirin 91.9% 94.2% 86.4% 93.2%
Heparin IV 98.5% 97.1% 98.7% 99.4%
Nitrates IV 100.0% 98.6% 100.0% 100.0%
b-Blockers 66.2% 62.6% 60.7% 63.2%
Ca antagonists 40.4% 43.2% 48.4% 59.9%
Medication after enrollment
Aspirin 97.1% 97.2% 94.2% 97.4%
Ticlopidin 5.1% 3.6% 3.4% 4.9%
Heparin IV 96.3% 97.1% 95.8% 97.7%
Nitrates IV 96.3% 97.1% 94.5% 98.4%
b-Blockers 66.9% 64.0% 63.0% 60.6%
Ca antagonists 42.6% 43.2% 50.6% 58.6%
CABG indicates coronary artery bypass grafting.
Figure 1. Lesion characteristics at baseline according to TnT
status.
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(P,0.001; Figure 2). TIMI flow #1 was documented for
15.6% of TnT-positive patients but only 5.1% of patients with
a TnT level #0.1 mg/L (P,0.001). For 22.4% of TnT-
positive patients, impaired TIMI flow was significantly im-
proved by treatment with abciximab (incidence of TIMI flow
#1, 16.1% versus 12.5%; P50.01). In contrast, for TnT-
positive patients in the placebo group, the incidence of
impaired TIMI flow increased from 14.9% to 17.1%
(P50.02). For TnT-negative patients, no significant differ-
ences were observed between the first and second angiogram,
independent of treatment group (Table 2).
Thrombus
At the time of randomization, 14.6% of the TnT-positive
patients had a visible thrombus versus 4.2% of TnT-negative
patients (P,0.001; Figure 3). Resolution of thrombus during
the treatment period before PTCA was particularly evident in
TnT-positive patients allocated to abciximab, with a relative
reduction of 63% (placebo, 224%; P,0.001; Figure 4).
Thrombus in TnT-negative patients was infrequent. No sig-
nificant reduction was achieved with placebo (P50.42) or
abciximab (P50.54).
Predictive Value of Angiogram and TnT Levels
Complex lesion characteristics (types B21/C) were linked to a
more adverse outcome (death or nonfatal AMI) for all investi-
gated time periods: before PTCA (OR, 1.7; 95% CI, 0.8 to 2.9;
P50.05); #72 hours after coronary intervention (OR, 2.1; 95%
CI, 1.4 to 3.5; P50.008); at 30-day follow-up (OR, 2.5; 95% CI,
1.3 to 3.1; P50.03), and at 6-month follow-up (OR, 1.7; 95%
CI, 0.9 to 2.8; P50.04) (Figure 5). In contrast, detection of
thrombus formation on baseline angiograms was not associated
with significantly increased cardiac risk at any time period:
before PTCA (OR, 1.2; 95% CI, 0.4 to 3.7; P50.15), #72 hours
of treatment (OR, 1.3; 95% CI, 0.3 to 3.5; P50.39), at 30-day
follow-up (OR, 1.2; 95% CI, 0.2 to 2.8; P50.52), and at
6-month follow-up (OR, 1.2; 95% CI, 0.1 to 2.7; P50.56). Only
failed resolution of thrombus before PTCA was significantly
predictive of PTCA-related complications (OR, 1.7; 95% CI, 1.2
to 3.5; P50.03). TnT was a powerful predictor of increased
cardiac risk at all assessment time points: before PTCA (OR,
4.9; 95% CI, 1.1 to 12.2; P50.005); at 72 hours after PTCA
(OR, 3.6; 95% CI, 1.5 to 8.2; P,0.001); at 30-day follow-up
(OR, 3.2; 95% CI, 1.4 to 6.8; P,0.001), and at 6-month
follow-up (OR, 2.3; 95% CI, 1.3 to 5.2; P,0.001).
When both TnT status and angiographic findings were
included in a stepwise logistic regression model, neither
complex lesion characteristics nor visibility of thrombus had
independent prognostic value for short- or long-term out-
comes. TnT status was identified as the only independent
prognostic marker for increased cardiac risk for all investi-
gated time periods.
Complex lesion characteristics (OR, 0.56; 95% CI, 0.11 to
1.05; P50.02) and TnT levels (OR, 0.23; 95% CI, 0.12 to
0.49; P,0.001) but not visibility of thrombus (OR, 0.67; 95%
CI, 0.25 to 1.25; P50.39) were predictive of efficacy of
abciximab treatment. Using multivariate analysis, only TnT
determination had independent predictive value. When TnT
level was forced into the model first, the introduction of
lesion characteristics did not improve the predictive value of
the statistical model (P50.49).
Discussion
The present analysis of this rather homogenous high-risk popu-
lation enrolled in the CAPTURE trial demonstrates a significant
relationship between angiographic lesion complexity, presence
of thrombus, and a TnT level .0.1 mg/L. Lesion types of
B21/C were documented in 72.0% of the patients with TnT
levels .0.10 mg/L. Classification according to lesion morphol-
Figure 2. TIMI flow at baseline according to TnT status.
Figure 3. Percent of patients with visible thrombus on qualifying
angiogram as related to TnT concentration measured at baseline.
Shaded bars indicate elevated TnT levels ($0.1 mg/L).
TABLE 2. TIMI Flow After 18 to 24 Hours of Allocated Treatment According to TnT Status
TnT-Positive (n5263) TnT-Negative (n5589)
TIMI Flow at Baseline Abciximab Placebo P TIMI Flow at Baseline Abciximab Placebo P
TIMI 0 (n519) 21 12 0.64 TIMI 0 (n510) 11 21 0.59
TIMI 1 (n522) 25 11 0.13 TIMI 1 (n520) 21 equal 0.87
TIMI 2 (n565) 23 11 0.16 TIMI 2 (n5119) 12 21 0.43
TIMI 3 (n5157) 19 24 ,0.001 TIMI 3 (n5440) 22 12 0.06
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ogy provided important prognostic information for estimating
patients’ short-term cardiac risk, particularly the risk associated
with the PTCA procedure (OR, 2.1; 95% CI, 1.4 to 3.5;
P50.008). However, TnT status was a stronger predictor of
cardiac risk relative to the angiographic findings. Patients with
elevated TnT concentrations were at increased risk for progres-
sion to myocardial infarction or death during the first 24 hours
before coronary intervention (OR, 4.9; 95% CI, 1.1 to 12.2;
P50.005); these patients were also at increased risk for throm-
botic complications associated with the procedure (OR, 3.6;
95% CI, 1.5 to 8.2; P,0.001).
A further finding of our study was support for the hypoth-
esis that TnT might be a surrogate marker for microemboli-
zation from liable thrombus formation.5,8 A significantly
greater accumulation of angiographically detectable throm-
bus was observed in patients with elevated TnT levels.
Patients with TnT values .0.10 mg/L had a 4-fold higher
incidence of visible thrombus in the qualifying angiogram
before randomization (14.6% versus 4.2%; P,0.001).
In the present study, there was a low incidence of throm-
bus, even in TnT-positive patients (14.3%). However, when
strict criteria are applied, as in the present study, angiography
is not a very sensitive method for the detection of thrombus.
The criterion “filling defect surrounded on 3 sites by con-
trast” precluded detection of a thrombus adhering to the
vessel wall. Neither intravascular ultrasound nor angioscopic
evaluation was performed in the CAPTURE trial; these
methods might have provided a higher sensitivity for the
detection of thrombus formation. However, despite its low
sensitivity for the detection of mural thrombus, angiography
remains highly specific for larger luminal thrombi.21,22
Additionally, qualifying angiograms in the CAPTURE trial
were obtained after patients had been treated with intravenous
heparin for a mean time of 12 hours (range, 2 to 48 hours).2
In the placebo group with another 18 to 24 hours of treatment
with heparin, thrombus formation resolved in 26.5% of the
patients. This finding demonstrates the treatment efficacy of
heparin alone with respect to the resolution of thrombus
formation. Accordingly, treatment with heparin in this study
population is likely to have reduced the incidence of throm-
bus even before the qualifying angiograms were obtained.
Given that TnT release is detectable for .7 days after
myocardial cell necrosis, the causal thrombus formation
might have already been resolved by heparin therapy before
study enrollment in several patients. Thrombi still visible at
the time of randomization might have been larger or more
resistant to the treatment with heparin and aspirin.
The angiographic findings of this study support the hypoth-
esis that TnT release in patients with unstable angina is
related to coronary thrombosis and consecutive embolization
leading to minor myocardial damage. In patients with unsta-
ble angina, inflammatory reactions promote plaque fissuring
or erosion, followed by exposure of thrombogenic contents
such as collagen to the circulation. Platelet activation and
adhesion result in formation of liable thrombus. Pathohisto-
logical studies have disclosed focal cell necroses distal in the
myocardium supplied by the culprit artery; they were attrib-
uted to repetitive embolization from such liable thrombi. Our
findings are consistent with the hypothesis that TnT release
might be a surrogate marker for microembolization from
liable thrombus formation. The increased cardiac risk of
TnT-positive patients may be related less to detected minor
myocardial damage than to causal high complexity of coro-
nary morphology in the culprit lesion.
Using multivariate analysis, including both angiographic find-
ings and patients’ TnT status, TnT elevation remained the only
independent and powerful predictor of increased cardiac risk
(Figure 5). Relative to the angiogram, determination of cardiac
TnT (and, presumably, likewise cardiac troponin I) must be
considered the superior marker, with a higher sensitivity for the
detection of probable unstable thrombus formation or high-risk
lesion morphology. Because angiograms are a poor descriptor of
true lesion complexity, it may be preferable to look at the
consequences of the lesion in terms of elevated TnT levels rather
than to assess angiographic characteristics.23–26
With regard to the efficacy of treatment with abciximab
varying in different subgroups of the CAPTURE trial, we
recently demonstrated that the documented treatment benefit
of abciximab was largely obtained among patients having
TnT concentrations .0.1 mg/L.27 Both thrombus resolution
and increase of TIMI flow, potential indicators for the
efficacy of treatment, were more pronounced in patients
receiving abciximab. Again, this was particularly evident in
those patients with TnT elevation. Thrombi that did not
resolve during pretreatment with heparin before randomiza-
tion were no longer detectable in 63.6% of patients with
Figure 4. Share of patients with detectable thrombus at baseline
and after 24 hours of allocated treatment according to TnT status.
Figure 5. Predictive value of TnT and angiographic findings:
adjusted ORs and 95% CIs regarding AMI-free survival at
6-month follow-up.
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elevated TnT levels after infusion therapy with abciximab
(placebo, 23.8%; P,0.001). In TnT-negative patients, inci-
dence of visible thrombus was low, and no difference was
documented for treatment with abciximab versus placebo.
However, treatment with abciximab was effective with re-
spect to the reduction of death and nonfatal AMI at 30-day
follow-up in both patients with and without visible thrombus
formation. This might, at least in part, be due to the relatively
low incidence of angiographically detectable thrombus for-
mation. In contrast, complex lesion characteristics served as a
significant predictor for benefit of treatment with abciximab.
Cardiac risk was elevated in patients with type B2 and C
lesions when patients were allocated to placebo (OR, 2.5;
95% CI, 1.3 to 3.1; P50.03), but it did not significantly differ
from patients with less complex lesions when they were given
abciximab (OR, 1.4; 95% CI, 0.7 to 1.9; P50.43). In
multivariate analysis, however, only TnT, not complex lesion
characteristics, provided a significant predictive way to iden-
tify the subgroup of patients who received the highest benefit
from treatment with abciximab (OR, 0.23 for TnT-negative
versus 1.26 for TnT-positive; P,0.001). Regarding the pre-
dictive value of lesion morphology, these findings contrast
with results from the more heterogeneous population enrolled in
the EPILOG (Evaluation in PTCA to Improve Long-term
Outcome by C7E3 GP IIb/IIIa receptor blockade) trial, indicat-
ing a reduction of early adverse ischemic events by abciximab
that was mainly independent of lesion morphology.28
In conclusion, the data presented here indicate that TnT
elevation was significantly linked to morphological complexity
of the target lesion and to visibility of thrombus formation, even
after prolonged treatment with heparin. We further suggest that
troponin release can be interpreted as a surrogate marker for
more complex lesion characteristics and for microembolization
from liable thrombus formation. Although failed resolution of
thrombus and complex lesion characteristics provide important
prognostic information, our data suggest that TnT determination
represents the independent and most powerful marker for the
prediction of cardiac risk. TnT, but not angiographic findings,
was predictive for efficacy of treatment with abciximab in
patients with unstable angina.
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